Figures & data
Figure 1 (A) Abdominal dynamic CT scan were performed on the three groups before and 7 days after operation (n = 4). (B) Tumor growth rate of each group (n = 4). (C) The number of intrahepatic metastases 7 days after operation (n = 4). *P < 0.05, **P < 0.01, ***P < 0.001.
![Figure 1 (A) Abdominal dynamic CT scan were performed on the three groups before and 7 days after operation (n = 4). (B) Tumor growth rate of each group (n = 4). (C) The number of intrahepatic metastases 7 days after operation (n = 4). *P < 0.05, **P < 0.01, ***P < 0.001.](/cms/asset/1ea9995e-837b-4d81-b425-1180530ff752/dcmr_a_12189913_f0001_c.jpg)
Figure 2 (A) Representative hematoxylin-eosin staining. Scale bar = 100 μm. (B) Tumor necrosis rate of each group. *P < 0.05.
![Figure 2 (A) Representative hematoxylin-eosin staining. Scale bar = 100 μm. (B) Tumor necrosis rate of each group. *P < 0.05.](/cms/asset/c5649da4-7e0d-41e7-8ea6-9e0b7d572779/dcmr_a_12189913_f0002_c.jpg)
Figure 3 (A) Immunofluorescence of CD31. Nucleus (blue area) and positive expression of CD31 (red area). Scale bar = 50 μm. (B) The percentages of CD31-positive area in VX2 tumor tissue. ***P < 0.001.
![Figure 3 (A) Immunofluorescence of CD31. Nucleus (blue area) and positive expression of CD31 (red area). Scale bar = 50 μm. (B) The percentages of CD31-positive area in VX2 tumor tissue. ***P < 0.001.](/cms/asset/442655e4-a407-4c77-ac65-5e9b162cfdee/dcmr_a_12189913_f0003_c.jpg)